Another phase II trial including 52 patients with c-Met-positive NSCLC showed that 9 patients (23%) achieved objective responses, with a median DoR of 8.7 months and a median PFS of 5.2 months [266]. The gene discussed is MET; the disease is non-small cell lung carcinoma.